LAVAL, Quebec / Jun 05, 2025 / Business Wire / Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 4, 2025. The detailed results of the votes received by proxy are as follows:
Election of Directors
Director Nominees | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
FOR | WITHHELD | FOR | WITHHELD | |
Daniel N. Chicoine | 5,432,232 | 301,172 | 94.75% | 5.25% |
Anthony E. Dobranowski | 5,455,219 | 278,185 | 95.15% | 4.85% |
John C. London | 5,427,266 | 306,138 | 94.66% | 5.34% |
Deborah Shannon-Trudeau | 5,463,225 | 270,179 | 95.29% | 4.71% |
Serge Verreault | 5,490,982 | 242,422 | 95.77% | 4.23% |
Reappointment of External Auditors
Outcome | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
FOR | WITHHELD | FOR | WITHHELD | |
Ernst & Young LLP reappointed | 6,388,758 | 49,767 | 99.23% | 0.77% |
Approval of the Continuation of Crescita’s Shareholder Rights Plan
Outcome | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
FOR | AGAINST | FOR | AGAINST | |
Shareholder Rights Plan approved | 5,481,368 | 252,036 | 95.60% | 4.40% |
About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information visit, www.crescitatherapeutics.com.
| Last Trade: | C$0.48 |
| Daily Change: | 0.03 6.67 |
| Daily Volume: | 48,100 |
| Market Cap: | C$9.090M |
August 06, 2025 May 23, 2025 March 18, 2025 November 06, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
